Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis

Samira B.L. Makanjuola, Sanni D. Ayodele, Farideh A. Javid, John O. Obafunwa, Mobolaji A Oludara, Abiodun O. Popoola

Research output: Contribution to journalArticle

Abstract

Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, treatment and survival. The present retrospective study was carried out to quantify the proportion of estrogen (ER), progesterone (PR), and human epithelial receptor 2 (HER2) expressions and their association with tumour grade, age, and tumour size in breast cancer patients in Nigeria. Materials and methods: The paraffin embedded tissue sections were analysed for breast cancer markers using monoclonal antibody SP1 for ER and SP2 for PR and polyclonal antibody ErbB2 for HER2. Results: A total of 286 breast cancer paraffin wax tissue sections were analysed for ER, PR and HER2 expression. Of all the tissue samples examined, 20 (7 were ER-positive, 6 (2.1 were PR-positive, 11 (3.8 were HER2-positive whereas 248 (87 were triple-negative breast carcinoma. ER- and PR-positivity was associated with early grade I and II tumours (P <0.010-0.009) and tumour sizes of <50mm (p <0.001). HER2-positivity was positively (P <0.009) associated with grade II tumours and negatively (P <0.0001) associated with grade III tumours. Triple-negative breast cancer was associated with grade III tumours (P <0.0001) and larger tumour sizes of > 50mm (P <0.0001). Conclusion: A small proportion of Nigerian women with breast cancer are ER/PR-positive which are associated with less aggressive, better prognosis and benefit from endocrine therapy. An even smaller proportion of patients with aggressive tumors were HER2-posivite but responsive to Herceptin treatment. Unfortunately, a very high proportion of cases were triple-negative which is associated with very aggressive tumours and no targeted treatment, which may explain the high mortality rates from breast cancer in Nigeria
LanguageEnglish
Pages122-127
Number of pages6
JournalJournal of Cancer Research Therapy
Volume2
Issue number8
DOIs
Publication statusPublished - 1 Aug 2014

Fingerprint

Breast Neoplasms
Progesterone
Estrogens
Neoplasms
Nigeria
Paraffin
Waxes
Therapeutics
Retrospective Studies
Monoclonal Antibodies
Survival
Mortality
Antibodies
Research

Cite this

Makanjuola, Samira B.L. ; Ayodele, Sanni D. ; Javid, Farideh A. ; Obafunwa, John O. ; Oludara, Mobolaji A ; Popoola, Abiodun O. / Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis. In: Journal of Cancer Research Therapy. 2014 ; Vol. 2, No. 8. pp. 122-127.
@article{4c43f8d5f2d24137838ec1849a0faf4d,
title = "Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis",
abstract = "Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, treatment and survival. The present retrospective study was carried out to quantify the proportion of estrogen (ER), progesterone (PR), and human epithelial receptor 2 (HER2) expressions and their association with tumour grade, age, and tumour size in breast cancer patients in Nigeria. Materials and methods: The paraffin embedded tissue sections were analysed for breast cancer markers using monoclonal antibody SP1 for ER and SP2 for PR and polyclonal antibody ErbB2 for HER2. Results: A total of 286 breast cancer paraffin wax tissue sections were analysed for ER, PR and HER2 expression. Of all the tissue samples examined, 20 (7 were ER-positive, 6 (2.1 were PR-positive, 11 (3.8 were HER2-positive whereas 248 (87 were triple-negative breast carcinoma. ER- and PR-positivity was associated with early grade I and II tumours (P <0.010-0.009) and tumour sizes of <50mm (p <0.001). HER2-positivity was positively (P <0.009) associated with grade II tumours and negatively (P <0.0001) associated with grade III tumours. Triple-negative breast cancer was associated with grade III tumours (P <0.0001) and larger tumour sizes of > 50mm (P <0.0001). Conclusion: A small proportion of Nigerian women with breast cancer are ER/PR-positive which are associated with less aggressive, better prognosis and benefit from endocrine therapy. An even smaller proportion of patients with aggressive tumors were HER2-posivite but responsive to Herceptin treatment. Unfortunately, a very high proportion of cases were triple-negative which is associated with very aggressive tumours and no targeted treatment, which may explain the high mortality rates from breast cancer in Nigeria",
author = "Makanjuola, {Samira B.L.} and Ayodele, {Sanni D.} and Javid, {Farideh A.} and Obafunwa, {John O.} and Oludara, {Mobolaji A} and Popoola, {Abiodun O.}",
year = "2014",
month = "8",
day = "1",
doi = "10.14312/2052-4994.2014-19",
language = "English",
volume = "2",
pages = "122--127",
journal = "Journal of Cancer Research Therapy",
publisher = "Noble Research",
number = "8",

}

Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis. / Makanjuola, Samira B.L.; Ayodele, Sanni D.; Javid, Farideh A.; Obafunwa, John O.; Oludara, Mobolaji A; Popoola, Abiodun O.

In: Journal of Cancer Research Therapy, Vol. 2, No. 8, 01.08.2014, p. 122-127.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Breast cancer receptor status assessment and clinicopathological association in Nigerian women: A retrospective analysis

AU - Makanjuola, Samira B.L.

AU - Ayodele, Sanni D.

AU - Javid, Farideh A.

AU - Obafunwa, John O.

AU - Oludara, Mobolaji A

AU - Popoola, Abiodun O.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, treatment and survival. The present retrospective study was carried out to quantify the proportion of estrogen (ER), progesterone (PR), and human epithelial receptor 2 (HER2) expressions and their association with tumour grade, age, and tumour size in breast cancer patients in Nigeria. Materials and methods: The paraffin embedded tissue sections were analysed for breast cancer markers using monoclonal antibody SP1 for ER and SP2 for PR and polyclonal antibody ErbB2 for HER2. Results: A total of 286 breast cancer paraffin wax tissue sections were analysed for ER, PR and HER2 expression. Of all the tissue samples examined, 20 (7 were ER-positive, 6 (2.1 were PR-positive, 11 (3.8 were HER2-positive whereas 248 (87 were triple-negative breast carcinoma. ER- and PR-positivity was associated with early grade I and II tumours (P <0.010-0.009) and tumour sizes of <50mm (p <0.001). HER2-positivity was positively (P <0.009) associated with grade II tumours and negatively (P <0.0001) associated with grade III tumours. Triple-negative breast cancer was associated with grade III tumours (P <0.0001) and larger tumour sizes of > 50mm (P <0.0001). Conclusion: A small proportion of Nigerian women with breast cancer are ER/PR-positive which are associated with less aggressive, better prognosis and benefit from endocrine therapy. An even smaller proportion of patients with aggressive tumors were HER2-posivite but responsive to Herceptin treatment. Unfortunately, a very high proportion of cases were triple-negative which is associated with very aggressive tumours and no targeted treatment, which may explain the high mortality rates from breast cancer in Nigeria

AB - Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, treatment and survival. The present retrospective study was carried out to quantify the proportion of estrogen (ER), progesterone (PR), and human epithelial receptor 2 (HER2) expressions and their association with tumour grade, age, and tumour size in breast cancer patients in Nigeria. Materials and methods: The paraffin embedded tissue sections were analysed for breast cancer markers using monoclonal antibody SP1 for ER and SP2 for PR and polyclonal antibody ErbB2 for HER2. Results: A total of 286 breast cancer paraffin wax tissue sections were analysed for ER, PR and HER2 expression. Of all the tissue samples examined, 20 (7 were ER-positive, 6 (2.1 were PR-positive, 11 (3.8 were HER2-positive whereas 248 (87 were triple-negative breast carcinoma. ER- and PR-positivity was associated with early grade I and II tumours (P <0.010-0.009) and tumour sizes of <50mm (p <0.001). HER2-positivity was positively (P <0.009) associated with grade II tumours and negatively (P <0.0001) associated with grade III tumours. Triple-negative breast cancer was associated with grade III tumours (P <0.0001) and larger tumour sizes of > 50mm (P <0.0001). Conclusion: A small proportion of Nigerian women with breast cancer are ER/PR-positive which are associated with less aggressive, better prognosis and benefit from endocrine therapy. An even smaller proportion of patients with aggressive tumors were HER2-posivite but responsive to Herceptin treatment. Unfortunately, a very high proportion of cases were triple-negative which is associated with very aggressive tumours and no targeted treatment, which may explain the high mortality rates from breast cancer in Nigeria

U2 - 10.14312/2052-4994.2014-19

DO - 10.14312/2052-4994.2014-19

M3 - Article

VL - 2

SP - 122

EP - 127

JO - Journal of Cancer Research Therapy

T2 - Journal of Cancer Research Therapy

JF - Journal of Cancer Research Therapy

IS - 8

ER -